Response Prediction in EBV-HLH Using Metabonomics Analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05677178

Enrollment

Registered

2023-01-10

Start date

2023-01-01

Completion date

2025-03-01

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV, Hemophagocytic Lymphohistiocytoses, Metabonomics

Keywords

Hemophagocytic Lymphohistiocytoses, EBV, matabonomics

Brief summary

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Detailed description

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Without early intervention, the median survival time is less than 2 months.Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Interventions

OTHERobservational

This study is an observational study without any intervention.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients who meet HLH-04 diagnostic criteria * EBV-DNA viral load in the peripheral blood \> 500 copies/mL * Informed consent obtained.

Exclusion criteria

* refuse to participate.

Design outcomes

Primary

Measure	Time frame	Description
Difference in metabonomics pattern between subgroups	2 months	Compare metabonomics pattern of the survival group with that of the death group, identify potential predictors of outcomes, and establish a survival prediction model in patients with EBV-HLH. Measure metabolite levels.
Difference in cytokine pattern between subgroups	2 months	Compare metabonomics and cytokine pattern of the survival group with that of the death group, identify potential predictors of outcomes, and establish a survival prediction model in patients with EBV-HLH. Measure cytokine levels.

Countries

China

Contacts

Primary ContactZhao Wang, MD

wangzhao@ccmu.edu.cn+861083138303

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026